Table of Content - Gm1 Gangliosidosis Treatment Market

GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study

This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026–2033)
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global GM1 gangliosidosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Gm1 Gangliosidosis Treatment Market Segmentation

By Product Type
- LYS-GM101
- PBGM01
- AXO-AAV-GM1
By Disease Type
- Type 1 GM1 Gangliosidosis
- Type 2 GM1 Gangliosidosis
- Type 3 GM1 Gangliosidosis
Global Gm1 Gangliosidosis Treatment Market, By Region
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa
Competitive Landscape
Company Profiles
- Axovant Gene Therapies Ltd.
- Passage Bio
- Lysogene

Table of Contents

Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

Market Purview

Report Description

Market Definition and Scope

Executive Summary

Market Snapshot, By Product Type
Market Snapshot, By Disease Type
Market Snapshot, By Region
Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Key Development
Epidemiology
Primary Research Insights

Patient Insights
Physician Insights
Manufacturer Insights

Global GM1 Glangliosidosis Treatment Market, By Product Type, 2021-2033 (USD Mn)

Introduction

Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends

LYS-GM101

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)

PBGM01

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)

AXO-AAV-GM1

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)

Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2021–2033 (USD Mn)

Introduction

Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022–2033
Segment Trends

Type 1 GM1 Gangliosidosis

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)

Type 2 GM1 Gangliosidosis

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)

Type 3 GM1 Gangliosidosis

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)

Global GM1 Glangliosidosis Treatment Market, By Region, 2021–2033 (USD Mn)

Introduction

Market Share Analysis, By Country, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Countries, 2022–2033

North America

Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)

U.S.
Canada

Europe

Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)

Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe

Latin America

Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)

Brazil
Mexico
Argentina
Rest of Latin America

Asia Pacific

Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)

GCC Countries
Israel
Rest of Middle East

Africa

Introduction
Market Size and Forecast, By Product Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Disease Type, 2021–2033 (USD Mn)
Market Size and Forecast, By Country, 2021–2033 (USD Mn)

Central Africa
South Africa
North Africa

Competitive Landscape

Company Profiles

Axovant Gene Therapies Ltd.

Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies

Passage Bio

Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies

Lysogene

Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies

*Browse 16 market data tables and 16 figures on “GM1 Glangliosidosis Treatment Market– Global forecast to 2033”.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now